Business Context and Reporting Period
This Form 8-K, filed on September 12, 2018, reports on events occurring on September 7, 2018. Evolent Health, Inc. (Evolent) entered into a definitive Agreement and Plan of Merger to acquire NCIS Holdings, Inc. (the Company). The transaction involves a merger where NCIS Holdings will become a wholly-owned subsidiary of Evolent Health LLC.
Key Financial Metrics and Transaction Terms
The filing details the consideration for the acquisition rather than standard operating financial metrics (revenue, profit, cash flow) for the reporting period.
- Cash Consideration: $120,000,000.
- Equity Consideration: 3,120,311 shares of Evolent Class B common stock and corresponding Class B common units. This equity portion is valued at approximately $77,352,500 based on a volume-weighted average price of $24.79 per share.
- Total Base Consideration: Approximately $197,352,500 (subject to working capital and debt adjustments).
- Earnout Consideration: Up to $20,000,000 contingent on the Company's 2019 operating results.
- Escrow Amount: $1,100,000 of the merger consideration will be held in escrow for indemnification purposes.
- Insurance: Evolent purchased a buyer-side representations and warranties insurance policy effective at closing.
Material Changes and Transaction Structure
The primary material change is the entry into a binding merger agreement. The transaction structure includes:
- Closing Date: Expected on the third business day following the satisfaction of conditions, but no earlier than October 1, 2018.
- Conditions Precedent: Approval by requisite equityholders, expiration of the Hart-Scott-Rodino waiting period, absence of legal impediments, and accuracy of representations and warranties.
- Financing: The merger is not subject to any financing condition.
- Shareholder Eligibility: Class B shares and units are restricted to "accredited investors." Non-accredited investors will receive cash in lieu of equity.
- Exchange Rights: Equityholders may exchange Class B shares/units for Class A shares at a 1:1 ratio via exchange agreements.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the consummation of the merger, which are subject to significant risks and uncertainties.
- Contingencies: The deal is subject to customary closing conditions, including regulatory approvals and shareholder votes. The earnout is contingent on 2019 operating performance.
- Risks: Risks include the possibility that the closing may be delayed or not occur, potential litigation, and the failure of the Company to meet operating targets for the earnout.
- Management Commentary: The filing references a press release (Exhibit 99.1) for further details but does not provide specific management commentary on financial outlook beyond the transaction terms.
- Unusual Items: The issuance of unregistered securities (Class B shares/units) is exempt under Section 4(a)(2) of the Securities Act.
Key Facts for Investor Verification
- Verify the final closing date and whether all regulatory conditions (including HSR) are satisfied.
- Confirm the final purchase price after post-closing adjustments for net working capital, cash, and indebtedness.
- Monitor the 2019 operating results of NCIS Holdings to determine the payout of the $20 million earnout.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific representations, warranties, and indemnification limitations.
- Check for any subsequent filings regarding the exchange of Class B securities for Class A securities by shareholders.